Silence Therapeutics Q2 2025 Earnings Report

Silence Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.21
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Silence Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $3.38 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Silence Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/21/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Silence Therapeutics (NASDAQ:SLN) plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.